Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01851330 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

A Phase 3 study of Chronic Hepatitis C Virus, sponsored by Gilead Sciences.

Completed
Registry status
Phase 3
Development phase
647
Enrollment target
20
Study locations

NCT01851330 is a Phase 3 study of Chronic Hepatitis C Virus that has completed, run by Gilead Sciences. The registered enrollment target is 647 participants, above the 147-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (340% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01851330, a Phase 3 study of Chronic Hepatitis C Virus, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 3
Development phase
647 participants
Enrollment target
20
Study locations

Study Summary

This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.

Conditions Studied

Chronic Hepatitis C Virus

Interventions

  • DRUG RBV
  • DRUG LDV/SOF

Study Locations (20)

California

  • - La Jolla
  • - Los Angeles
  • - Palo Alto
  • - Sacramento
  • - San Diego
  • - San Francisco

Florida

  • - Gainesville
  • - Jacksonville
  • - Miami
  • - Orlando
  • - Wellington

Georgia

  • - Atlanta
  • - Decatur
  • - Marietta

Colorado

  • - Aurora
  • - Englewood

Alabama

  • - Birmingham

District of Columbia

  • - Washington D.C.

Illinois

  • - Chicago

Indiana

  • - Indianapolis

Trial Details

FieldValue
Enrollment Target 647 participants
Start Date 2013-05
Est. Completion 2014-03
Phase Phase 3

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01851330

The ClinicalTrials.gov registry entry for NCT01851330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 647 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (340% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Hepatitis C Virus appearing as the primary indexed condition, and to 2 interventions - of which RBV is the first listed.

NCT01851330 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT01851330 about?

NCT01851330 is a clinical study titled "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)". This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.

What is the current status of trial NCT01851330?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 647 participants. The study started on 2013-05. Estimated completion is 2014-03.

What conditions does trial NCT01851330 study?

This clinical trial studies the following conditions: Chronic Hepatitis C Virus.

What interventions are being tested in trial NCT01851330?

The interventions under investigation include: RBV (DRUG), LDV/SOF (DRUG).

Who is sponsoring clinical trial NCT01851330?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01851330 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Hepatitis C Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Hepatitis C Virus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.